Bayer Receives FDA Approval for BETACONNECT - First and Only Electronic Autoinjector In Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment

Bayer HealthCare has announced U.S. Food and Drug Administration (FDA) approval of BETACONNECT, the first and only electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS). BETACONNECT will be available exclusively to BETASERON (interferon beta-1b) patients beginning in early 2016.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news